STOCK TITAN

CTT Pharmaceutical delays quarterly report

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
NT 10-Q

Rhea-AI Filing Summary

CTT Pharmaceutical Holdings, Inc. (CTTH) said it could not file its quarterly report for the period ended September 30, 2026, by the prescribed deadline without unreasonable effort or expense. The company expects to file the Form 10-Q within the five-calendar-day extension period permitted under Rule 12b-25.

Filing extension 5 calendar days Expected filing window for the Form 10-Q under Rule 12b-25.
Rule 12b-25 regulatory
"five-calendar-day extension period permitted under Rule 12b-25"
Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 12b-25

 

Commission File Number: 333-292497

 

NOTIFICATION OF LATE FILING

 

☐ Form 10-K

☐ Form 20-F

☐ Form 11-K

☒ Form 10-Q

☐ Form 10-D

☐ Form N-SAR

☐ Form N-CSR

 

For Period Ended: September 30, 2026

☐

Transition Report on Form 10-K

☐

Transition Report on Form 10-Q

☐

Transition Report on Form 20-F

☐

Transition Report on Form 11-K

☐

Transition Report on Form N-SAR

For the Transition Period Ended: _______________________________________

 

Nothing in this form shall be construed to imply that the Commission

has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I

REGISTRANT INFORMATION

 

Full name of registrant

CTT Pharmaceutical Holdings, Inc.

Former name if applicable

 

Address of principal executive office

1646 W Snow Ave. Suite 138

City, state and zip code

Tampa, FL. 33606

 

 

 

 

PART II

RULE 12b-25 (b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)

 

 

(a)

The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

☒

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-SAR or Form N-CSR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the 5th calendar day following the prescribed due date; and

 

(c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III

NARRATIVE

 

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within the prescribed time period.

 

CTT Pharmaceutical Holdings, Inc.  (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the period ended September 30, 2026 (the “Quarterly Report”) within the prescribed time period without unreasonable effort or expense. The Company expects to file the Quarterly Report within the five-calendar-day extension period permitted under Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

 

PART IV

OTHER INFORMATION

 

(1)

Name and telephone number of person to contact in regard to this notification

 

Ryan Khouri

 

(813)

 

606-0060

(Name)

 

(Area Code)

 

(Telephone Number)

 

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

 

☒ Yes    ☐ No

 

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

 

 

 

☐ Yes    ☒ No

 

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 
2

 

 

CTT Pharmaceutical Holdings, Inc.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated: November 17, 2026

By:

/s/ Ryan Khouri

 

 

Name:

Ryan Khouri

 

 

Title:

Chief Executive Officer

(Principal Executive, Financial and Accounting Officer)

 

 

 
3

 

Keep reading